Rabies virus glycoprotein 29 (RVG29) promotes CAR-T immunotherapy for glioma

Chimeric antigen receptor T cell (CAR-T) therapy has limited efficacy for treating glioma because of the infiltrative nature of the blood –brain barrier (BBB) and T cell exhaustion. Conjugation with rabies virus glycoprotein (RVG) 29 enhances the brain-related efficacy of various agents. Here we assess whether RVG enhances the ability of CAR-T cells to cross the BBB and improves their immunotherapy. We generated 70R CAR-T cells (ant i-CD70 CAR-T modified with RVG29) and validated their tumor-killing efficacy in vitro and in vivo.

Source: Translational Research - March 25, 2023 Category: Research Authors: Feng Ji, Luxia Xu, Kaili Long, Fan Zhang, Miaomiao Zhang, Xiao Lu, Mingyue Xia, Jiannan Chen, Yu Du, Yong Tang, Heming Wu, Yan Shi, Ruiting Ma, Jun Li, Zhengliang Chen, Bin Xu, Qi zhang, Junqing Liang, Shaochang Jia, Zhigang Hu, Zhigang Guo Source Type: research